ClinicalTrials.Veeva

Menu

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes (PRACET)

I

Inova Fairfax Hospital

Status and phase

Enrolling
Phase 3

Conditions

Premature Rupture of Membrane

Treatments

Drug: Azithromycin
Drug: Erythromycin

Study type

Interventional

Funder types

Other

Identifiers

NCT06273891
23-08-WC-0198 (Other Identifier)
INOVA-2023-58

Details and patient eligibility

About

The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM.

Full description

Preterm pre-labor rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-fourth to one-third of preterm births. PPROM is associated with significant maternal and neonatal morbidities, including chorioamnionitis, endometritis, neonatal sepsis, prematurity-related pathologies. In the absence of labor or indication for immediate delivery, patients who present at less than 34 weeks gestational age are treated with antibiotics to prolong pregnancy until 34 weeks when the risks of prematurity are decreased. Based on randomized trials, both the American College of Obstetrics and Gynecology (ACOG) and the Society of Maternal Fetal Medicine (SMFM) recommend IV ampicillin and IV erythromycin for 2 days, followed by an oral regimen of amoxicillin and erythromycin for 5 days. Due to the recent limited availability of erythromycin, azithromycin has been used a substitute. There have been observational studies showing no difference in duration of pregnancy between azithromycin and erythromycin, however no randomized controlled trial has been carried out to our knowledge. This study performs a cluster randomized controlled trial to examine the efficacy of azithromycin versus erythromycin as a component of the "latency antibiotics" used to prolong pregnancy in PPROM patients.

Enrollment

140 estimated patients

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pregnancy at 22 weeks 0 days to 32 weeks 6 days of gestation.
  • Rupture of membranes confirmed by biochemical testing.
  • Membrane rupture within the past 36 hours.
  • Cervical dilation 3 cm or less and 4 or fewer contractions within 60-minutes at the time of admission.
  • Age ≥18 and <50 years.

Exclusion criteria

  • Non-reassuring fetal heart tracing, vaginal bleeding, chorioamnionitis or any indication for delivery at admission.
  • Allergy to penicillin, erythromycin, or azithromycin.
  • Multiple gestations.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

140 participants in 2 patient groups

Erythromycin
Active Comparator group
Description:
Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days
Treatment:
Drug: Erythromycin
Azithromycin
Active Comparator group
Description:
Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days
Treatment:
Drug: Azithromycin

Trial contacts and locations

2

Loading...

Central trial contact

Ellen M Murrin, DO; Antonio Saad, MD, MBA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems